Figure 3 | Scientific Reports

Figure 3

From: Rational design of a nanoparticle platform for oral prophylactic immunotherapy to prevent immunogenicity of therapeutic proteins

Figure 3

Cellular mechanisms of tolerogenic lipid particles. Expansion of LAP+ Tregs (a,b) and Tr1 (c) following in vitro treatment with tolerogenic lipid particles, which led to the suppression of CD4+ (d) and CD8+ T cells (e). Data are represented as mean ± SD. Representative graphs from 2 independent experiments was shown. (f–h) Frequency of LAP+ Tregs, Tr1, and CD8+ Tregs co-expressing LAG3 and CD49b, respectively, in the MLN of animals receiving tolerogenic lipid particles. (i,j) Absolute number of B cells and antibody-producing plasma cells, respectively, in the MLN of animals receiving tolerogenic lipid particles. Data are represented as mean ± SEM. Statistical significance was denoted by P < 0.05 (*) by a one-way ANOVA test followed by Tukey’s post-hoc analysis on log-transformed data.

Back to article page